Swiss drug giant Novartis already sports one of the world’s top-selling blood pressure drugs, the $2-billion-plus blockbuster Diovan. Now it aims to consolidate its advantage in the $40 billion hypertension drug market by developing a powerful new type of blood pressure drug that may help millions of patients whose blood pressure isn’t fully controlled by existing medications.
